De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

National Health Investors Beheer

Beheer criteriumcontroles 4/4

De CEO National Health Investors' is D. Mendelsohn, benoemd in Aug2015, heeft een ambtstermijn van 9.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.08M, bestaande uit 24% salaris en 76% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.19% van de aandelen van het bedrijf, ter waarde $ 7.46M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7.1 jaar en 8 jaar.

Belangrijke informatie

D. Mendelsohn

Algemeen directeur

US$2.1m

Totale compensatie

Percentage CEO-salaris	24.0%
Dienstverband CEO	9.2yrs
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	7.1yrs
Gemiddelde ambtstermijn bestuur	8yrs

Recente managementupdates

Recent updates

National Health Investors GAAP EPS of $0.04 misses by $0.65, revenue of $70.66M misses by $4.97M

Feb 21

6%-Yielding National Health Investors: No Pain, No Gain

Feb 06

National Health Investors: Why This 5.5%-Yielding Rebound Is Worth A Shot

Sep 10

National Health Investors Q2 Earnings Preview

Aug 07

National Health Investors: A 5.8% Yield, And Little Else

Jun 29

Analyse CEO-vergoeding

Hoe is D. Mendelsohn's beloning veranderd ten opzichte van National Health Investors's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	US$128m
Mar 31 2024	n/a	n/a	US$132m
Dec 31 2023	US$2m	US$500k	US$136m
Sep 30 2023	n/a	n/a	US$105m
Jun 30 2023	n/a	n/a	US$110m
Mar 31 2023	n/a	n/a	US$92m
Dec 31 2022	US$3m	US$418k	US$66m
Sep 30 2022	n/a	n/a	US$71m
Jun 30 2022	n/a	n/a	US$68m
Mar 31 2022	n/a	n/a	US$85m
Dec 31 2021	US$3m	US$398k	US$112m
Sep 30 2021	n/a	n/a	US$142m
Jun 30 2021	n/a	n/a	US$154m
Mar 31 2021	n/a	n/a	US$159m
Dec 31 2020	US$2m	US$386k	US$185m
Sep 30 2020	n/a	n/a	US$190m
Jun 30 2020	n/a	n/a	US$190m
Mar 31 2020	n/a	n/a	US$186m
Dec 31 2019	US$2m	US$375k	US$160m
Sep 30 2019	n/a	n/a	US$155m
Jun 30 2019	n/a	n/a	US$154m
Mar 31 2019	n/a	n/a	US$152m
Dec 31 2018	US$2m	US$350k	US$154m
Sep 30 2018	n/a	n/a	US$155m
Jun 30 2018	n/a	n/a	US$153m
Mar 31 2018	n/a	n/a	US$154m
Dec 31 2017	US$2m	US$340k	US$159m

Compensatie versus markt: De totale vergoeding ($USD 2.08M ) D. } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.79M ).

Compensatie versus inkomsten: De vergoeding van D. is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

D. Mendelsohn (62 yo)

9.2yrs

Tenure

US$2,084,567

Compensatie

Mr. D. Eric Mendelsohn has been a Director at National Health Investors, Inc since February 17, 2021. Mr. Mendelsohn serves as the Chief Executive Officer and President at National Health Investors Inc. si...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
D. Mendelsohn	President	9.2yrs	US$2.08m	0.19% $ 7.3m
John Spaid	Executive VP of Finance	8.6yrs	US$1.30m	0.083% $ 3.2m
Kevin Pascoe	Executive VP & Chief Investment Officer	7.7yrs	US$1.19m	0.12% $ 4.6m
David Travis	Senior VP & Chief Accounting Officer	4.4yrs	US$1.02m	0.035% $ 1.3m
Kristin Gaines	Senior VP & Chief Transaction Officer	1.7yrs	US$1.05m	0.13% $ 4.8m
Dana Hambly	Director of Investor Relations	5.2yrs	geen gegevens	geen gegevens
Kimberly Ouimet	Director of Corporate Compliance & Human Resources	9.8yrs	geen gegevens	geen gegevens
Michelle Kelly	Senior Vice President of Investments	7.1yrs	geen gegevens	geen gegevens
Susan Sidwell	Corporate Secretary	no data	geen gegevens	geen gegevens
Colleen Schaller	Real Estate Transaction Manager	5.2yrs	geen gegevens	geen gegevens

7.1yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van NHI is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
D. Mendelsohn	President	3.7yrs	US$2.08m	0.19% $ 7.3m
W. Adams	Independent Chairman of the Board	33.8yrs	US$175.86k	1.85% $ 70.3m
Robert Adams	Independent Director	4.4yrs	US$175.86k	1.19% $ 45.4m
Charlotte Swafford	Independent Director	4.4yrs	US$175.86k	0.24% $ 9.1m
Robert McCabe	Independent Director	23.7yrs	US$190.86k	0.073% $ 2.8m
Robert Webb	Independent Director	33.8yrs	US$180.86k	0.27% $ 10.1m
Tracy M. Colden	Independent Director	2.3yrs	US$175.86k	0.097% $ 3.7m
James Jobe	Independent Director	11.5yrs	US$180.86k	0.063% $ 2.4m

8.0yrs

Gemiddelde duur

74.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van NHI wordt beschouwd als ervaren (gemiddelde ambtstermijn 8 jaar).

National Health Investors Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Senior VP & Chief Transaction Officer exercised options and sold US$752k worth of stock

Executive VP of Finance exercised options and sold US$1.3m worth of stock

Executive VP & Chief Investment Officer exercised options and sold US$1.9m worth of stock

Independent Director exercised options to buy US$767k worth of stock.

Independent Director exercised options and sold US$656k worth of stock

National Health Investors, Inc., Annual General Meeting, May 22, 2024

Recent updates

National Health Investors, Inc. to Report Q3, 2024 Results on Nov 05, 2024

National Health Investors: From Struggles To Strength

Senior VP & Chief Transaction Officer exercised options and sold US$752k worth of stock

Upcoming dividend of US$0.90 per share

Executive VP of Finance exercised options and sold US$1.3m worth of stock

Executive VP & Chief Investment Officer exercised options and sold US$1.9m worth of stock

Price target increased by 12% to US$78.50

Independent Director exercised options to buy US$767k worth of stock.

New minor risk - Shareholder dilution

National Health Investors, Inc. has completed a Follow-on Equity Offering in the amount of $171 million.

National Health Investors, Inc. has filed a Follow-on Equity Offering.

Second quarter dividend of US$0.90 announced

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

National Health Investors, Inc. Provides Earnings Guidance for the Full Year 2024

Independent Director exercised options and sold US$656k worth of stock

National Health Investors, Inc. to Report Q2, 2024 Results on Aug 06, 2024

National Health Investors, Inc.(NYSE:NHI) dropped from Russell Small Cap Comp Growth Index

Land & Buildings Investment Management Comments on National Health Investors’ Supplemental Proxy Statement

First quarter dividend of US$0.90 announced

National Health Investors: The Lack Of Upside Seems Obvious To Me Here

National Health Investors, Inc. Announces Dividend for the Second Quarter of 2024, Payable on August 2, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Land & Buildings Issues Letter to Shareholders of National Health Investors Announcing its Intention to Vote Against Two Directors at 2024 Annual Meeting

National Health Investors, Inc. to Report Q1, 2024 Results on May 06, 2024

National Health Investors, Inc., Annual General Meeting, May 22, 2024

Upcoming dividend of US$0.90 per share

Price target increased by 7.2% to US$62.00

Insufficient new directors

Independent Director recently bought US$587k worth of stock

Price target increased by 7.5% to US$59.86

Fourth quarter dividend of US$0.90 announced

National Health: Lots To Love, But Valuation Still On The High Side

Full year 2023 earnings: EPS and revenues exceed analyst expectations

National Health Investors, Inc. Provides Earnings Guidance for the Year 2024

National Health Investors, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Upcoming dividend of US$0.90 per share at 6.3% yield

Catch The Senior Housing Rebound With National Health Investors

National Health Investors: 7% Yielding REIT Has Improved On Most Metrics

National Health Investors, Inc. Provides Earnings Guidance for the Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

National Health Investors, Inc. Announces Its Fourth Quarter Dividend, Payable on January 26, 2024

National Health Investors, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Upcoming dividend of US$0.90 per share at 7.1% yield

National Health Investors: Enjoy This Solid 7%+ Yield, For Now

New minor risk - Earnings quality

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

National Health Investors, Inc. Announces Third Quarter 2023 Dividend, Payable on November 3, 2023

National Health Investors, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Upcoming dividend of US$0.90 per share at 6.8% yield

National Health: What We Got Wrong With This Healthcare REIT

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

National Health Investors, Inc. Announces Second Quarter 2023 Dividend, Payable on August 4, 2023

Full year 2022 earnings: EPS misses analyst expectations

National Health Investors GAAP EPS of $0.04 misses by $0.65, revenue of $70.66M misses by $4.97M

6%-Yielding National Health Investors: No Pain, No Gain

National Health Investors, Inc. to Report Q4, 2022 Results on Feb 21, 2023

Upcoming dividend of US$0.90 per share

Independent Director recently bought US$57k worth of stock

National Health Investors, Inc. (NYSE:NHI) acquired Bickford of Virginia Beach from Bickford Senior Living, L.L.C. for $14 million.

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

National Health Investors, Inc. Announces Fourth Quarter 2022 Dividend, Payable on January 27, 2023

Consensus EPS estimates fall by 21%

National Health Investors, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Upcoming dividend of US$0.90 per share

National Health Investors: Why This 5.5%-Yielding Rebound Is Worth A Shot

Chief Investment Officer exercised options and sold US$220k worth of stock

Price target increased to US$62.71

Independent Director recently bought US$99k worth of stock

Second quarter 2022 earnings: EPS and revenues miss analyst expectations